I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part ...

The setback is a potential plus for Bristol Myers Squibb, which in September won Food and Drug Administration approval of Cobenfy, the first new kind of treatment for schizophrenia ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product ...

For decades, the medical world has avidly searched for groundbreaking treatments against one of humanity’s most resilient ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

IBN ? Annovis Bio, Inc. ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's ...

An electronic nose created by scientists in Tartu may be able to diagnose serious neurological diseases such as Parkinson's ...

Factors associated with ageing that can increase falls risk include loss of muscle strength and balance, orthostatic hypotension, and visual and functional impairments. Older people may also have ...

AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September 2024 is now available on the company's ...